Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: A preliminary study

C. Gambaro, C. Bilardi, P. Dulbecco, E. Iiritano, P. Zentilin, C. Mansi, P. Usai, S. Vigneri, V. Savarino

Research output: Contribution to journalArticlepeer-review


Background. Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category. This might be useful to reduce the duration of anti-Helicobacter therapies. Aims. The aim of this study was to assess whether there is the possibility of shortening a rabeprazole-based triple therapy from 7 to 4 days without compromising its efficacy in the eradication of Helicobacter pylori infection. Patients. A total of 128 consecutive dyspeptic patients with H. pylori infection were recruited for this controlled, randomized, open and parallel-group trial comparing the efficacy of two durations of the same rabeprazole-based triple therapy. Methods. All patients were subdivided to receive a combination of rabeprazole 20 mg twice daily, clarithromycin 250 mg twice daily and metronidazole 500 mg twice daily (RCM) for 4 days (n = 63) and for 7 days (n = 65). At baseline, they underwent breath 13C-urea test and endoscopy with biopsies for rapid urease testing and histology to confirm infection with H. pylori. Eradication was determined by a negative 13C-urea breath test within 28-32 days after the end of therapy. Results. Overall eradication rates were similar for patients treated with the 4- and the 7-day periods (intention-to-treat and per-protocol analyses showed a success rate of 81% versus 78% and 88% versus 85%, respectively; P = NS). Tolerance was similar in both groups. Most adverse events were mild to moderate, and only two patients were withdrawn because of them. Conclusions. The eradication rate of the 4-day regimen was equivalent to that of the same 7-day regimen based on rabeprazole plus clarithromycin and metronidazole. Therefore, the 4-day regimen of RCM seems to give us the possibility of adopting a shorter-than-usual duration of therapy against H. pylori.

Original languageEnglish
Pages (from-to)763-767
Number of pages5
JournalDigestive and Liver Disease
Issue number11
Publication statusPublished - Nov 2003


  • Eradication therapy
  • Helicobacter pylori
  • Rabeprazole

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: A preliminary study'. Together they form a unique fingerprint.

Cite this